Soraya Meghari¹, Benoît Desnues¹, Christian Capo¹, Georges E. Grau^1,2, Didier Raoult¹, Jean-Louis Mege¹

European Cytokine Network, Vol.17, No.4, pp. 253-259, 2006, DOI:10.1684/ecn.2006.0041

Abstract Q fever is an infectious disease caused by Coxiella burnetii, which may become chronic when cytokine network and cell-mediated immune responses are altered. Chemokines, such as Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES, CCL5) and Monocyte Chemoattractant Protein-1 (MCP-1, CCL2), are specialized in the trafficing of peripheral blood mononuclear cells (PBMC), and are associated with T cell polarization that is essential for intracellular survival of C. burnetii. The present study investigated whether or not the infection status (no infection and acute or chronic infection with C. burnetii) of donors, affected the production of the two… More >

Ivar Bleumer¹, Pieter H. M. de Mulder², Peter F. A. Mulders¹

Canadian Journal of Urology, Vol.13, Suppl.2, pp. 57-62, 2006

Abstract Renal cell carcinoma (RCC) presents as localized disease in 54% of the cases. For these patients, surgery is the primary curative treatment. Unfortunately, up to 65% of all patients show recurrent disease. For metastatic RCC non-specific immunotherapy is currently the treatment of choice. Nevertheless, several new modalities, e.g. WX-G250, oncophage and anti-angiogenic compounds like sunitinib and sorafenib are being explored with favorable results. Still, their place in the primary treatment of advanced RCC has yet to be determined. Because of the high percentage of recurrent disease, there is a need to identify these patients with… More >

Pierre I. Karakiewicz^1,2, Felix K.-H. Chun^2,3, Alberto Briganti², Paul Perrotte¹, Michael McCormack¹, François Bénard¹, Luc Valiquette¹, Markus Graefen³, Fred Saad¹

Canadian Journal of Urology, Vol.13, Suppl.2, pp. 18-25, 2006

Abstract Introduction: Several nomograms have been developed to predict PCa related outcomes. Neural networks represent an alternative.
Methods: We provide a descriptive and an analytic comparison of nomograms and neural networks, with focus on PCa detection.
Results: Our results indicate that nomograms have several advantages that distinguish them from neural networks. These are both quantitative and qualitative.
Conclusion: In the field of PCa detection, nomograms appear to outweigh the benefits of neural networks. However, the neural network methodology represents a valid alternative, which should not be underestimated. More >

Glenn M. Cannon, Nikhil B. Amesur, Timothy D. Averch¹

Canadian Journal of Urology, Vol.13, No.1, pp. 2984-2987, 2006

Abstract Percutaneous renal surgen; can be utilized as treatment for a variety of urologic conditions. Percutaneous nephrolithotomy remains the treatment of choice for many large and complex renal calculi. Despite having a low overall complication rate, postoperative bleeding can occur. We report a case of significant hemorrhage from a renal pseduoaneurysm in a patient requiring anticoagulation following percutaneous nephrolithotomy. The bleeding was controlled by percutaneous coil embolization. Current management recommendations of postoperative hemorrhage following percutaneous renal surgery are reviewed. More >

Scott Berry¹, Tricia Waldron², Eric Winquist³, Himu Lukka⁴, on behalf of the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group⁵

Canadian Journal of Urology, Vol.13, No.4, pp. 3180-3188, 2006

Abstract Purpose: A systematic review of randomized controlled trials (RCTs) was performed to assess the benefits of bisphosphonate therapy in men with hormone-refractory prostate cancer (HRPC).
Methods: The literature was searched to identify RCTs or meta-analyses comparing treatment with bisphosphonates to placebo or no treatment.
Results: Ten trials that studied clodronate (five trials, 404 patients), pamidronate (two trials, 350 patients), alendronate (one trial, 49 patients), etidronate (one trial, 51 patients), and zoledronic acid (one trial, 643 patients) in men with HRPC and bone metastases met the eligibility criteria. Pain response was the most frequently reported primary outcome (eight… More >

M. G. RÍOS-DURÁN*, A. R. HERNÁNDEZ-TÉLLEZ**, C. A. MARTÍNEZ-PALACIOS**, L. G. ROSS***

BIOCELL, Vol.30, Suppl.S, pp. 149-155, 2006

Abstract This article has no abstract. More >

PEDRO CARRIQUIRIBORDE, ALICIA RONCO

BIOCELL, Vol.30, Suppl.S, pp. 97-109, 2006

Abstract This article has no abstract. More >

I.A. VEGA*, M.C. DAMBORENEA**, C. GAMARRA-LUQUES*, E. KOCH*, J.A. CUETO, A. CASTRO-VAZQUEZ*

BIOCELL, Vol.30, Suppl.S, pp. 367-375, 2006

Abstract This article has no abstract. More >

MARCOS S. DREON¹, HORACIO HERAS^1,2, RICARDO J. POLLERO¹

BIOCELL, Vol.30, Suppl.S, pp. 359-365, 2006

Abstract This article has no abstract. More >

PABLO R. MARTÍN*, CLAUDIO G. DE FRANCESCO**

BIOCELL, Vol.30, Suppl.S, pp. 337-343, 2006

Abstract This article has no abstract. More >